Open AccessHodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature
Author(s) -
Edyta Paczkowska,
Michał Janowski,
Katarzyna Karpińska-Kaczmarczyk,
Małgorzata Ryłów,
Barbara Zdziarska,
Wojciech Poncyljusz,
Bogusław Machaliński
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s300320
Subject(s) - medicine , dasatinib , nilotinib , dacarbazine , lymphoma , imatinib , chronic myeloid leukaemia , vinblastine , hodgkin lymphoma , oncology , chemotherapy , myeloid leukemia
Incidences of chronic myeloid leukaemia (CML) after treatment of Hodgkin lymphoma (HL) are well described. Here, we report a case of secondary HL in a patient with CML treated with dasatinib as a third-line treatment.